We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
Fields »
 

Field

Term
Gene name

Class

Subclass

Chromosome

External id

In atlas

Reliability

Reliability

Reliability

Validation

Method

Validation

Method

Validation

Method

Validation

Location

Searches

Tissue

Cell type

Expression

Tissue

Specificity

Cell line

Specificity

Cancer

Specificity

Tissue

Detectable

Cell line

Detectable

Cancer

Detectable

Cancer

Prognosis

Category

Score

Score

Score

Antibodies

Column

 
 
ABOUT
HELP
BLOG
  • THE HUMAN PROTEOME
  • THE HUMAN TISSUES
  • THE HUMAN CELL
  • HUMAN PATHOLOGY
  • PROTEIN CLASSES
  • PROTEIN EVIDENCE
    • NEWS
    • BLOG
    • EVENTS
    • PRESS ROOM
    • LEARN
    • DICTIONARY
    • METHODS
    • CELL LINES
  • THE PROJECT
  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS
  • PUBLICATION DATA
  • ANTIBODY SUBMISSION
  • ANTIBODY AVAILABILITY
  • LINKS
  • CONTACT
  • TECHNICAL DATA
  • ANTIBODY VALIDATION
  • ASSAYS & ANNOTATION
  • DISCLAIMER
  • DOWNLOADABLE DATA
  • HELP & FAQ
  • LICENCE & CITATION
  • PRIVACY STATEMENT
  • RELEASE HISTORY
PSMB3
  • premium

    TISSUE

  • CELL

  • PATHOLOGY

PATHOLOGY ATLAS MELANOMA

GENE/PROTEIN

Antibody validation

Dictionary

Melanoma

MELANOMA - Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival, using best separation (to the left) and median separation (to the right). Patients were divided based on level of expression into one of the two groups "low" or "high". Below each Kaplan-Meier plot, corresponding expression cutoff, 5-year survival for patients with high expression, 5-year survival for patients with low expression and log-rank P value are displayed. For melanoma and glioma, 3-year survival is shown. The survival analysis is described in Assays & Annotation.

The tabs at the top of the survival analysis section can be used to switch between the different cancer subtypes.

Best separation

Median separation

Expression cutoffi

5-year survival for patients with higher expression than the expression cutoff.

91.6 FPKM 99.8 FPKM

3-year survival highi

5-year survival for patients with higher expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

42% 35%

3-year survival lowi

5-year survival for patients with lower expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

39% 44%

Log-rank P valuei

Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.

2.02e-1 4.04e-1

Interactive survival scatter plot (individual patient data)i

The Scatter Survival plot shows the clinical status for all individuals in the patient cohort, based on the same data as in the Kaplan-Meier plots. Living patients are shown in blue and deceased patients in red. The x-axis shows the expression levels (FPKM) of the investigated gene at the time of diagnosis and the y-axis shows the number of years of survival (living years) after the diagnosis.

Individual patient data is displayed in an interactive plot and can be filtered by clicking on one or several category buttons to the left. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be changed to "x linear" by clicking on the "x log" button on the left. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.




Stage:



TCGA RNA samplesi

RNA-seq data is reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .

Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.

Average FPKM

107.9

Number of samples

102

Samples

Sample

Description

FPKM

TCGA-BF-A1Q0-01A 80 years, male, white, stage:iic 362.9
TCGA-EB-A4OZ-01A 42 years, female, white, stage:iiic 274.7
TCGA-EB-A85I-01A 66 years, male, white, stage:iic 240.4
TCGA-EB-A4OY-01A 65 years, female, white, stage:iiib 232.7
TCGA-IH-A3EA-01A 61 years, male, white, stage:iic 213.2
TCGA-EB-A3Y7-01A 86 years, female, white, stage:iiib 204.5
TCGA-EB-A3XE-01A 77 years, female, white, stage:iia 176.9
TCGA-BF-AAP4-01A 61 years, male, white, stage:iic 169.1
TCGA-EB-A3XC-01A 74 years, male, white, stage:iic 167.5
TCGA-EB-A85J-01A 66 years, female, white, stage:iib 165.1
TCGA-BF-AAP7-01A 76 years, female, white, stage:iic 161.4
TCGA-EB-A4P0-01A 82 years, male, white, stage:iic 160.2
TCGA-BF-A9VF-01A 77 years, male, white, stage:iic 159.5
TCGA-BF-AAOU-01A 73 years, female, white, stage:iic 159.3
TCGA-XV-A9W2-01A 81 years, male, white, stage:i 152.3
TCGA-ER-A194-01A 77 years, male, white 151.4
TCGA-EB-A6QZ-01A 76 years, female, white, stage:iia 148.1
TCGA-XV-AAZY-01A 76 years, female, white, stage:iiic 147.4
TCGA-EB-A553-01A 62 years, male, white, stage:iic 139.9
TCGA-GN-A263-01A 24 years, male, white, stage:iv 136.8
TCGA-XV-AAZW-01A 62 years, female, white, stage:ii 133.7
TCGA-DA-A960-01A 73 years, male, white, stage:iib 133.6
TCGA-EB-A3HV-01A 37 years, male, white, stage:iic 132.2
TCGA-BF-A1PZ-01A 71 years, female, white, stage:iib 129.2
TCGA-EB-A41A-01A 90 years, male, white, stage:iic 125.8
TCGA-ER-A2NB-01A 57 years, male, white, stage:iiib 125.0
TCGA-BF-A1PX-01A 56 years, male, white, stage:iiib 124.7
TCGA-EB-A41B-01A 76 years, female, white, stage:iic 123.7
TCGA-FR-A728-01A 54 years, female, white, stage:iiib 119.8
TCGA-EB-A82B-01A 58 years, female, asian, stage:iii 117.6
TCGA-BF-AAP2-01A 62 years, male, white, stage:iib 117.6
TCGA-BF-A5ER-01A 63 years, male, white, stage:iic 113.7
TCGA-EB-A42Z-01A 49 years, male, asian, stage:iiic 113.3
TCGA-EB-A5UM-01A 48 years, female, white, stage:iic 112.5
TCGA-EB-A97M-01A 66 years, male, white, stage:iic 111.8
TCGA-EB-A42Y-01A 73 years, female, asian, stage:iic 110.6
TCGA-EB-A6R0-01A 58 years, female, white, stage:iic 109.6
TCGA-GN-A4U5-01A 61 years, female, white, stage:ib 109.4
TCGA-EB-A3XB-01A 63 years, male, white, stage:ii 107.8
TCGA-WE-A8K4-01A 85 years, male, white, stage:iib 107.3
TCGA-GN-A26C-01A 77 years, male, white, stage:iiic 106.2
TCGA-BF-A1PU-01A 46 years, female, white, stage:iic 106.1
TCGA-EB-A1NK-01A 48 years, male, white, stage:iic 105.3
TCGA-EB-A3XF-01A 57 years, male, white, stage:iic 103.6
TCGA-EB-A44P-01A 58 years, female, white, stage:iic 103.4
TCGA-EB-A6QY-01A 71 years, male, white, stage:iic 102.8
TCGA-EB-A299-01A 63 years, male, white, stage:iia 102.5
TCGA-EB-A57M-01A 56 years, male, asian, stage:iiib 102.1
TCGA-GF-A769-01A 39 years, male, white, stage:iic 101.4
TCGA-EB-A4IS-01A 77 years, male, white, stage:iib 101.0
TCGA-EB-A3Y6-01A 56 years, female, white, stage:iic 100.3
TCGA-EB-A3XD-01A 53 years, female, white, stage:iic 99.3
TCGA-EB-A5VU-01A 56 years, male, asian, stage:iiib 98.6
TCGA-BF-A5EO-01A 65 years, male, white, stage:iic 98.2
TCGA-BF-AAP8-01A 58 years, male, white, stage:iic 95.7
TCGA-XV-AAZV-01A 56 years, female, white, stage:ii 95.5
TCGA-XV-A9W5-01A 51 years, male, white, stage:i/ii nos 95.0
TCGA-BF-A3DJ-01A 36 years, female, white, stage:iiib 93.2
TCGA-FR-A726-01A 90 years, male, white, stage:iic 90.0
TCGA-BF-A3DM-01A 63 years, male, white, stage:iia 89.3
TCGA-BF-A3DL-01A 84 years, female, white, stage:iiib 88.4
TCGA-D9-A4Z2-01A 50 years, male, white, stage:iiic 88.0
TCGA-EB-A51B-01A 53 years, male, white, stage:iic 87.4
TCGA-BF-A5ES-01A 76 years, female, white, stage:iic 85.7
TCGA-EB-A5SF-01A 78 years, female, white, stage:iic 85.4
TCGA-BF-AAOX-01A 83 years, male, white, stage:iic 84.2
TCGA-GN-A8LN-01A 68 years, male, white, stage:iic 81.3
TCGA-BF-AAP6-01A 55 years, male, white, stage:iii 80.5
TCGA-EB-A44N-01A 59 years, male, white, stage:iic 80.4
TCGA-EB-A5SE-01A 73 years, male, white, stage:iib 79.7
TCGA-EB-A4IQ-01A 42 years, female, asian, stage:iiib 78.7
TCGA-FR-A3R1-01A 69 years, male, white, stage:iic 78.3
TCGA-ER-A19K-01A 79 years, female, white, stage:iic 77.6
TCGA-BF-A5EQ-01A 63 years, male, white, stage:iic 77.1
TCGA-BF-AAP1-01A 86 years, male, white, stage:iic 75.1
TCGA-ER-A42H-01A 77 years, male, white 74.5
TCGA-D3-A5GT-01A 43 years, male, white, stage:iiic 74.0
TCGA-HR-A5NC-01A 90 years, female 72.5
TCGA-EB-A82C-01A 70 years, female, asian, stage:iic 72.0
TCGA-FS-A1ZN-01A 43 years, male, white, stage:iiia 71.4
TCGA-EB-A5FP-01A 65 years, female, white, stage:iv 70.5
TCGA-EB-A24C-01A 56 years, male, white 70.2
TCGA-FR-A2OS-01A 49 years, female, white, stage:iic 69.7
TCGA-GF-A2C7-01A 48 years, male, white, stage:iic 69.3
TCGA-EB-A550-01A 75 years, female, white, stage:iic 68.8
TCGA-EB-A551-01A 78 years, female, white, stage:iiic 68.4
TCGA-ER-A196-01A 64 years, female, white, stage:iic 67.4
TCGA-BF-A1PV-01A 74 years, female, white, stage:iic 66.7
TCGA-YG-AA3N-01A 67 years, male, stage:iic 65.8
TCGA-D9-A3Z4-01A 54 years, male, white, stage:iiic 64.7
TCGA-BF-A5EP-01A 75 years, female, white, stage:iiic 63.8
TCGA-EB-A4XL-01A 56 years, female, white, stage:iic 62.9
TCGA-XV-A9VZ-01A 90 years, female, white, stage:ii 58.0
TCGA-BF-A3DN-01A 81 years, female, white, stage:iiic 56.8
TCGA-EB-A431-01A 34 years, male, white, stage:iic 55.6
TCGA-ER-A2NF-01A 53 years, male, white, stage:iiib 54.9
TCGA-FW-A5DX-01A 71 years, male, white, stage:iiic 52.7
TCGA-D9-A4Z3-01A 73 years, female, white, stage:iiic 52.6
TCGA-EB-A24D-01A 72 years, male, white, stage:iiib 51.7
TCGA-EB-A44O-01A 69 years, male, white, stage:iib 50.6
TCGA-ER-A19T-01A 51 years, male, white, stage:iv 45.8
TCGA-D9-A4Z5-01A 68 years, male, white, stage:iib 41.1
Show all

MELANOMA - Protein expressioni

A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.

Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

 

Antibody HPA042775

Antibody HPA048147

 Antibody staining
  High
  Medium
  Low
  Not detected
   
 Intensity
  Strong
  Moderate
  Weak
  Negative
   
 Quantity
  >75%
  75%-25%
  <25%
  Rare
  Negative
   
 Location
  Cytoplasmic/membranous,nuclear
  Cytoplasmic/membranous
  Nuclear
  None
   

Click images for details











































Contact

  • BLOG
  • PRESS ROOM
  • contact@proteinatlas.org

The Project

  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS
  • DOWNLOADABLE DATA

The Human Protein Atlas

  • ANTIBODY AVAILABILITY
  • LICENCE & CITATION
  • HELP & FAQ
The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg foundation.